Guggenheim Capital LLC raised its stake in shares of Allergan (NYSE:AGN) by 24.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 311,000 shares of the company’s stock after purchasing an additional 61,245 shares during the period. Guggenheim Capital LLC owned 0.09% of Allergan worth $50,873,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of AGN. Focused Wealth Management Inc increased its position in shares of Allergan by 4,444.4% during the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after acquiring an additional 800 shares during the last quarter. BB&T Investment Services Inc. grew its holdings in shares of Allergan by 1,308.2% in the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after purchasing an additional 641 shares in the last quarter. Acropolis Investment Management LLC acquired a new position in shares of Allergan in the fourth quarter valued at approximately $153,000. Field & Main Bank acquired a new position in shares of Allergan in the fourth quarter valued at approximately $155,000. Finally, Zions Bancorporation grew its holdings in shares of Allergan by 1,115.6% in the third quarter. Zions Bancorporation now owns 936 shares of the company’s stock valued at $192,000 after purchasing an additional 859 shares in the last quarter. 77.97% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider William Meury sold 58,879 shares of Allergan stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total transaction of $9,457,144.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brent L. Saunders acquired 3,300 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were bought at an average price of $152.53 per share, for a total transaction of $503,349.00. The disclosure for this purchase can be found here. Insiders have purchased 8,095 shares of company stock worth $1,258,081 over the last 90 days. 0.36% of the stock is currently owned by company insiders.
NYSE:AGN traded down $3.61 during trading hours on Friday, hitting $161.52. The stock had a trading volume of 2,105,830 shares, compared to its average volume of 2,920,951. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Allergan has a 1-year low of $142.81 and a 1-year high of $256.80. The company has a market capitalization of $57,521.17, a price-to-earnings ratio of 9.88, a price-to-earnings-growth ratio of 1.18 and a beta of 1.18.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The business had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same quarter last year, the company earned $3.90 earnings per share. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. equities analysts anticipate that Allergan will post 15.58 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.78%. Allergan’s dividend payout ratio (DPR) is 17.61%.
A number of research analysts recently issued reports on the stock. Leerink Swann lifted their price target on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. JPMorgan Chase set a $265.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research report on Thursday, March 15th. Vetr downgraded shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price objective for the company. in a research report on Wednesday, January 10th. Cantor Fitzgerald reiterated a “hold” rating and issued a $191.00 price target on shares of Allergan in a research report on Tuesday, February 6th. Finally, Credit Suisse Group set a $214.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Monday, January 22nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $224.02.
COPYRIGHT VIOLATION NOTICE: “Guggenheim Capital LLC Has $50.87 Million Position in Allergan (AGN)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/guggenheim-capital-llc-has-50-87-million-stake-in-allergan-plc-agn.html.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.